Page 15 - Aurobindo Pharma

Top stock picks by Religare Broking: Buy Dabur, sell Sept Futures for DLF

Here are the weekly stock recommendations by Religare Broking

Aurobindo Pharma gains nearly 8% on growth prospects in US market

The completion of Sandoz acquisition and new product launches are triggers

Aurobindo Q1 profit up 39.5% at Rs 636 crore on strong revenue growth

Revenue from operations rose 28.1% year-on-year to Rs 5,444.6 crore during the quarter under review

Aurobindo Pharma confident of all-round growth in the US market

Aurobindo had reported Rs 19,563.6 crore in revenues in FY19 with an year-on-year growth of 18.5 per cent

Carcinogens in drug: US FDA seeks full re-evaluation in all Aurobindo units

Firm may have a tough task ahead improving manufacturing practices across the board through remediation running into months and years

Aurobindo Pharma gets warning letter from USFDA for Andhra facility

Aurobindo Pharma share price fell as much as 7.7 per cent to Rs 578.75

USFDA move not to hurt growth, new product nods to be delayed: Aurobindo

The company's stock took a beating after the USFDA pointed out data integrity lapses at the firm's formulations facility in Telangana's Bachupally

Aurobindo Pharma confident of growth despite regulatory action, drug recall

The company said it was confident that the contamination in valsartan will not spread to other products

Aurobindo Pharma gets 10 observations from USFDA for Unit 3 in Hyderabad

None of the observations are repetitive and are more procedural in nature, Aurobindo Pharma said

Growth across geographies keeps analysts positive on Aurobindo Pharma

Product launches, acquisitions are expected to drive US, EU prospects

FDA designates Aurobindo's 3 facilities as 'Official Action Indicated'

According to FDA's definitions, Official Action Indicated means "objectionable conditions were found and regulatory and/or administrative sanctions by FDA are indicated" during inspections

Aurobindo's strong European, US prospects keeping analysts bullish

As the pricing pressure in US generics market recedes, the company is also expected to fair well, say analysts, who see growth impetus coming from its recent acquisitions in the US and Europe

Aurobindo Pharma acquires 7 oncology products from US company for $300 mn

The product portfolio is expected to generate a revenue of around $100 million for first 12 months after completion of the transaction for Aurobindo

Lacunae in Aurobindo Pharma's Medak facility in Andhra, says FDA report

Besides, the report said preparative apparel was not worn as necessary to protect drug products from contamination

Aurobindo acquires Apotex Inc's biz in 5 European countries for 74 mn euros

BS ReporterHyderabad, 14 July: Aurobindo Pharma Limited announced today that its step-down subsidiary Agile Pharma B V(Netherlands ) signed a definitive agreement to acquire from Canadian pharmaceuticals company Apotex International Inc. its commercial operations and certain supporting infrastructure in five European countries for Euro 74 million(Rs 5.93 billion) in an all cash deal. The company expects to close the transaction in 3-6 months.The acquisition is in line with Aurobindo's strategy to strengthen and grow its European business and to expand in Eastern Europe, the company said.The acquisition includes a portfolio of over 200 prescription drugs and 88 OTC products and an additional pipeline of over 20 products which are expected to be launched over the next two years, besides a manufacturing facility in Leiden the Netherlands, with capabilities across manufacturing and packaging and capacity of 1.8 billion tablets per annum.With the acquisition of Apotex Inc's commercial ...

Aurobindo Pharma: US sales, European biz suggest drivers are in place

The acquired business is estimated to have annual sales of euro 130 million, according to analysts, and will add to Aurobindo's prospects in Europe

Aurobindo acquires Apotex's commercial operations in 5 European countries

Aurobindo Pharma had inked a binding agreement on July 14, 2018, to acquire five of Apotex' European businesses

Aurobindo Pharma's Q3 profit surges 19.69% to Rs 712 crore on robust sales

Revenues from operations increased 21.5 percent to 5,269.7 crore during the quarter under review as compared to Rs 4336.1 crore in the year ago period

Aurobindo Pharma's Q3 profit surges 19.69% to Rs 712 crore on robust sales

'We have delivered a robust revenue growth of 22%', said Aurobindo Pharma MD N Govindarajan

Aurobindo Pharma to acquire oncology products from US-based firm in $300 mn

Acrotech will be acquiring the product portfolio on a debt free and cash free basis, Aurobindo Pharma Ltd said in a regulatory filing